MONMOUTH JUNCTION, NJ--(Marketwire - March 05, 2013) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, today announced that Dr. Phillip Chan, Chief Executive Officer, will present at the Long Island Capital Alliance (LICA) Health Care Capital Forum on March 8, 2013. The capital forum will be held in collaboration with The Center for Advanced Sensor Technologies at Stony Brook University.
Date and Time:
March 8, 2013, 8:00 a.m. - 10:30 a.m.
The RXR Corporate Center
68 South Service Rd., Melville, New York
The presenting companies to be showcased at LICA's Health Care Capital Forum were selected by LICA for this event from a wide selection of developing medical technology, life sciences and health care information technology companies on Long Island and the nearby region. Several of the presenting companies provide best-in-class solutions to enhance medical related diagnostics and therapies as well as health care administration and productivity advancements. Each of the companies selected for presentation will provide a discussion of their technology, product of service, a financial overview and catalysts for significant growth.
For more information or to register for the event please contact your LICA representative or register online by visiting http://www.licapital.org/licapital/.
About the Long Island Capital Alliance:
Since 1984, the Long Island Capital Alliance (www.licapital.org), formerly known as Long Island Venture Group, has been promoting business growth on Long Island. LICA seeks to create a productive and business-friendly environment that will afford area businesses access to the resources necessary to compete successfully in today's markets. LICA serves as a focal point for the exchange of ideas among new and existing business enterprises, successful entrepreneurs, investors, and service providers. Through quarterly capital forums and special meetings, LICA brings together members of the region's business community, and has been recognized as the place to turn to when small businesses need equity, debt, or other financing, or for investors to find an attractive investment opportunity.
LICA's mission is to encourage economic development on Long Island by facilitating capital formation for a broad range of companies in various industries, from early stage to mature middle market closely held and publicly-traded businesses. LICA accomplishes this primarily through education, networking, quarterly capital forums, periodic special educational meetings, and alliances with other regional organizations. LICA brings together members of the region's business community and serves as the finance arm for significant local business and organizations.
For more information on LICA and its next event, please contact LICA today or register online.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses commonly seen in the intensive care unit such as sepsis and infection, influenza, severe lung injury, trauma, burn injury, and pancreatitis. Its purification technology is based upon biocompatible, highly porous polymer beads that can efficiently remove toxic substances from blood and other bodily fluids. The Company's flagship product CytoSorb®, a first-in-class extracorporeal cytokine filter compatible with standard hemodialysis machines, has achieved European Union CE Mark regulatory approval and is now being commercialized in Europe. The goal of the CytoSorb® cytokine filter is to prevent or treat multiple organ failure, the leading cause of death in the intensive care unit, by reducing the excessive production of cytokines, or "cytokine storm," that could otherwise lead to deadly inflammation, organ injury, and death. Organ failure represents one of the most serious unmet medical needs in modern medicine, claiming millions of lives around the world, at a cost of hundreds of billions of dollars, each year. By actively addressing one of the most important underlying causes of organ failure, CytoSorb® represents a potentially revolutionary advance in the treatment of critical illnesses.
CytoSorbents has been awarded contracts from both DARPA and the US Army, and continues to invest significantly in its research and development pipeline. One of its most advanced products under development is HemoDefend, a blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and improve the safety of "old" blood by removing many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.
CytoSorb® and HemoDefend are just two of a number of different polymers the Company has developed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com.